Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A phase II study to assess the efficacy and safety of Surufatinib combined with Sintilimab as
a second-line treatment in patients with advanced MSS-Type CRC.